SAN JOSE, CA, UNITED STATES, November 15, 2022 /EINPresswire.com/ —
Today, Gator Bio, Inc. announced the launch of Gator® AAV Ratio Kit, High Sensitivity AAV Kit and High Sensitivity AAV9 Kit for empty vs full ratio determination and titer, respectively. The assays run on FDA 21 CFR Part 11 compliant Gator® Prime and Gator® Plus biolayer interferometry (BLI) instruments. This is the only automated single platform solution in the market capable of accurate and easy determination of titer and empty vs full ratios at every stage of the AAV development and production.
The automated Gator® High Sensitivity AAV Kit and High Sensitivity AAV9 Kit enable titer determination with the widest dynamic range for serotypes 1-10 in crude and purified samples. This kit fits into every stage of the AAV processing workflow, and the titer measurements correlate well with the gold standard methods.
The Gator® AAV Ratio Kit is an innovative empty vs full method that easily and accurately measures ratios from 5-100% full capsids in crude and purified samples. Along with its simplicity, good AUC correlation, short time-to-result, and cost effectiveness, the Gator® AAV Ratio Kit will fundamentally change how this analysis is routinely done.
Enabling gene therapy developers and manufacturers with cutting-edge tools is Gator Bio’s focus. “There are many challenges and new demands in AAV and other vector analytics, and we are dedicated to developing practical solutions leveraging Gator’s next-gen BLI and novel chemistry know-how” said Dr. Hong Tan, CEO of Gator Bio. “We are singularly focused on delivering easy, efficient and cost-effective solutions”.
Detailed info for the newly released solutions along with Gator Bio’s complete portfolio of products can be found at –https://www.gatorbio.com/applications/gene-therapy/
About Gator Bio, Inc.
Gator Bio is a life sciences company providing analytical solutions to accelerate the development of therapeutics and diagnostics. The Gator instruments and biosensors enable real-time analysis of biomolecular interactions providing information on affinity, kinetics, concentration, and epitope binning, etc. Most importantly, Gator Bio’s analytical capabilities enable better and faster characterization of drug candidates and viral vector analytics, thus providing greater value in drug development and gene therapy applications, where existing methods have limitations in throughput, performance, and cost. The company is headquartered in Palo Alto, California. For more information, please visit www.gatorbio.com.
SOURCE Gator Bio, Inc.
Media and Investor Relations Contact:
Subodh Nimkar, Marketing Director
+1 650 575 0827